TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12775122
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g MCT and 5 g LCT (5M5L)
Study: 12775122
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g MCT in mayonnaise or margarine
Study: 12775122
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g LCT (10L)
Study: 7744189
Drug: Low-dose methylprednisolone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose methylprednisolone (1 mg.kg‐1 q.d.)
Study: 7744189
Drug: High-dose methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methylprednisolone (6 mg.kg‐1 q.d.)
Study: 16296709
Drug: Amlodipine 1.25
Normalized name: levamlodipine 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 1.25 mg once daily
Study: 16296709
Drug: Amlodipine 2.5
Normalized name: amlodipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 2.5 mg once daily
Study: 6125171
Drug: Metoprolol 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 150 mg twice daily
Study: 3540229
Drug: Pindolol 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol 7.5 mg twice daily
Study: 30378136
Drug: Simulated fine
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated fine fragrance containing Lim‐OOHs at 1260 ppm (3.0 μg/cm2)
Study: 30378136
Drug: Simulated fine
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated fine fragrance containing Lim‐OOHs at 420 ppm (0.99 μg/cm2)
Study: 30378136
Drug: Simulated fine
Normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simulated fine fragrance containing Lim‐OOHs at 140 ppm (0.33 μg/cm2)
Study: 30378136
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls exposed to the highest dose (1260 ppm)
Study: 28893134
Drug: Mepolizumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (100 mg)
Study: 11474056
Drug: SACA -
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SACA - administered to children aged 11 and older
Study: 11474056
Drug: SACA -
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SACA - administered to children aged 9 and 10 years
Study: 27183915
Drug: Ligation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligation of the appendicular base with Lapro‐Clips (L‐C group)
Study: 24355439
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Lactobacillus casei 01, 10^8 CFU daily for 8 weeks)
Study: 22536930
Drug: Both antiretroviral
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both antiretroviral and antidepressant treatment
Study: 22536930
Drug: Antidepressant adherence
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant adherence
Study: 20660052
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (25, 50, 125, 300, and 600 mg) administered weekly for 20 weeks
Study: 15735108
Drug: DMM (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMM (daily multiple micronutrient supplements)
Study: 15735108
Drug: DI (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: DI (10 mg of iron supplement daily)
Study: 15735108
Drug: Placebo (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (daily placebo supplement)
Study: 12846338
Drug: Ezetimibe 10
Normalized name: ezetimibe 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe 10 mg once daily for 12 weeks
Study: 10228127
Drug: Inhaled leukotriene
Normalized name: Leukotriene D4
DrugBank: Leukotriene D4 (DB11858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled leukotriene D4 (LTD4)
Study: 8689812
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg itraconazole orally once a day for 4 days
Study: 2014978
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial agent (Control)
Study: 30648627
Drug: oral ibandronate
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral ibandronate (150 mg)
Study: 24286286
Drug: Polychromatic light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polychromatic light treatment (611-650 nm or 570-850 nm, normalized to ∼ 9 J/cm²)
Study: 22316322
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention (energy‐ and protein‐enriched diet, oral nutritional supplements, calcium‐vitamin D supplement, telephone counseling by a dietitian) for 3 months after discharge
Study: 12045414
Drug: Various controller
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various controller medications for asthma treatment; specific medications and dosages not mentioned
Study: 26636532
Drug: Eumastós (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eumastós (combination of boswellic acid, betaine, and myo-inositol)
Study: 8405011
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg capsule) after 48 h abstention
Study: 8405011
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg capsule) after 12 h abstention
Study: 1881996
Drug: Caffeine (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (250 mg capsule)
Study: 3950073
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg every 6 hours
Study: 30059240
Drug: Virtual reality-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality-based cue exposure therapy (VR-CET)
Study: 30059240
Drug: Additional cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional cognitive behavioral therapy (A-CBT)
Study: 18094990
Drug: Oral antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral antibiotic prophylaxis (gyrase inhibitor)
Study: 18094990
Drug: Intravenous antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotic prophylaxis (gyrase inhibitor)
Study: 15933555
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose HRV vaccine (10 focus-forming units)
Study: 15933555
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose HRV vaccine (10 focus-forming units)
Study: 14569951
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg, increased to 100 mg if unsatisfactory response)
Study: 11452854
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of rt‐PA intraoperative injection into the opened basal subarachnoid cisterns following aneurysm clipping
Study: 11452854
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no rt‐PA treatment)
Study: 19453623
Drug: Ketoconazole treatment
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole treatment (3 and 6 months)
Study: 19453623
Drug: Ketoconazole treatment
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketoconazole treatment (6 months)
Study: 8803897
Drug: Chloroquine diphosphate
Normalized name: CHLOROQUINE DIPHOSPHATE, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine diphosphate (CDP) 250 mg/day
Study: 30041682
Drug: Citrus aurantium
Normalized name: Citrus aurantium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citrus aurantium + Caffeine (CA + C) (100 mg of CA and 100 mg of C)
Study: 15715187
Drug: Budesonide (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (800 microg twice daily for 4 weeks)
Study: 11966502
Drug: 28 tablets
Normalized name: RED 28
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 tablets (42 g) of sodium phosphate
Study: 11966502
Drug: 32 tablets
Normalized name: phosphorus 32
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 tablets (48 g) of sodium phosphate
Study: 2405462
Drug: Betadine solution
Normalized name: Betadine Solution 10% SwabAid
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betadine solution standardized
Study: 31826369
Drug: 12.5% oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5% oral carbohydrate drink
Study: 21411615
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (double-strength, 54% juice, 835 mg total polyphenols, 94 mg anthocyanins, 480 mL/d for 4 weeks)
Study: 21411615
Drug: Placebo beverage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo beverage (480 mL/d for 4 weeks)
Study: 21411615
Drug: Cranberry juice
Normalized name: cranberry juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cranberry juice (single 480-mL portion)
Study: 11392270
Drug: Drifting sinusoidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drifting sinusoidal grating background stimulation during computer game training for 10 days (2 sessions of 20 minutes daily)
Study: 11392270
Drug: Placebo group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo group with neutral background during computer game training for 10 days (2 sessions of 20 minutes daily)
Study: 9271751
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of blood conservation strategies; specific interventions not detailed.
Study: 29650060
Drug: Pre-treatment gastrostomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment gastrostomy tube feeding
Study: 29650060
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding plus as-required nasogastric tube feeding
Study: 28629132
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (2800 IU daily for eight weeks)
Study: 19099850
Drug: Pulmonary surfactant
Normalized name: Pulmonary surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary surfactant (PS) treatment in preterm infants (n=28)
Study: 19099850
Drug: Pulmonary surfactant
Normalized name: Pulmonary surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary surfactant (PS) treatment in term and late-preterm infants (n=8)
Study: 12451480
Drug: Rubitecan 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rubitecan 1.5 mg/m(2) per day orally
Study: 8813496
Drug: Oral methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral methylprednisolone (100 mg per day initially, dosage reduction every 3 days; n = 15)
Study: 8813496
Drug: Thiamine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamine (100 mg per day; n = 33)
Study: 1827103
Drug: Clarithromycin 250
Normalized name: clarithromycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 250 mg orally (500 mg for lung tissue), administered every 12 h for three days.
Study: 1827103
Drug: Roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 150 mg orally, administered every 12 h for three days.
Study: 31399091
Drug: CHF6001 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 800 μg
Study: 31399091
Drug: CHF6001 1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6001 1600 μg
Study: 26712982
Drug: Gabapentin 600
Normalized name: gabapentin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 600 mg capsule 1 hour before surgery
Study: 21943111
Drug: Restrictive fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive fluid strategy (4 ml/kg/hour of Ringer's lactate solution)
Study: 21943111
Drug: Conventional fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluid strategy (12 ml/kg/hour of Ringer's lactate solution)
Study: 18588512
Drug: ACEi (angiotensin‐converting
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACEi (angiotensin‐converting enzyme inhibitors)
Study: 18588512
Drug: ARBs (angiotensin
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARBs (angiotensin II receptor blockers)
Study: 16515395
Drug: HTT-blocking antidepressants
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTT-blocking antidepressants (SSRIs, TCAs)
Study: 15260082
Drug: Ketamine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.3 mg/kg/hr) and Propofol (initial rate of 10 mg/kg/hr)
Study: 15260082
Drug: Placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline) and Propofol (initial rate of 10 mg/kg/hr)
Study: 11729708
Drug: Infloran Berna
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infloran Berna (10^9 Lactobacillus acidophilus and 10^9 Bifidobacterium infantis, one capsule tid for 4 days)
Study: 11729708
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (parenteral rehydration only)
Study: 8219661
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acid based lipid emulsion (100 ml/day with 2.1 g eicosapentaenoic (EPA) and 21 g docosahexaenoic acid (DHA))
Study: 8219661
Drug: Conventional n-6
Normalized name: 18:3 (n-6)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional n-6 lipid emulsion (EPA + DHA < 0.1 g/100 ml)
Study: 2887189
Drug: epanolol 400
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol 400 mg
Study: 2887189
Drug: epanolol 200
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol 200 mg
Study: 2887189
Drug: epanolol 400
Normalized name: epanolol
DrugBank: Epanolol (DB13757)
Approvals — FDA: no, EMA: no, PMDA: no
Description: epanolol 400 mg and atenolol 100 mg
Study: 27072143
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release morphine (IRM)
Study: 24939433
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg isoflavones/day (supplements)
Study: 24939433
Drug: 48 mg
Normalized name: betaine 648 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 48 mg isoflavones/day (soy foods)
Study: 23933107
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) for 12 sessions
Study: 23933107
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) for 12 sessions
Study: 23933107
Drug: Overall predictor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall predictor of treatment outcome
Study: 16619561
Drug: sEGFR levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sEGFR levels below 45 ng/mL
Study: 16619561
Drug: sEGFR levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sEGFR levels below 45 ng/mL and elevated serum HER‐2/neu ECD (>15 ng/mL)
Study: 16619561
Drug: sEGFR levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sEGFR levels below 45 ng/mL in estrogen receptor-positive tumors
Study: 16619561
Drug: sEGFR levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: sEGFR levels below 45 ng/mL in estrogen receptor-positive tumors with elevated HER‐2/neu ECD
Study: 2017337
Drug: Regimen A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A: vancomycin 250 mg, tobramycin 75 mg, colistin 1 million IU, nystatin
Study: 2017337
Drug: Regimen B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen B: vancomycin 125 mg, tobramycin 75 mg, colistin 1 million IU, nystatin
Study: 618711
Drug: Stroma-free hemoglobin
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroma-free hemoglobin (SFH) infusion (250 ml administered slowly intravenously)
Study: 618711
Drug: Stroma-free hemoglobin
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stroma-free hemoglobin (SFH) infusion
Study: 618711
Drug: Serum albumin
Normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum albumin (250 ml administered to control group)
Study: 28765029
Drug: 2-stage surgery
Normalized name: SAGE
DrugBank: Sage (DB10982)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-stage surgery (sequential cervical and thoracic decompressions)
Study: 14723482
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine administered at 9-10 months
Study: 14723482
Drug: MMR vaccine
Normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMR vaccine administered at 15-18 months
Study: 9469983
Drug: Potato +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato + 100 g butter
Study: 9469983
Drug: Potato +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato + 40 g olive oil
Study: 9469983
Drug: Potato +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato + 50 g butter
Study: 9469983
Drug: Potato +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potato + 80 g olive oil
Study: 7893263
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg vitamin B6 (pyridoxine hydrochloride)
Study: 2516308
Drug: Metronidazole (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (6 g total, intraoral application six times)
Study: 2516308
Drug: Irradiation twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irradiation twice a day
Study: 28397104
Drug: Omeprazole (OME)
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole (OME) 40 mg administered postoperatively
Study: 23843495
Drug: G‐CHOP (obinutuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CHOP (obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Study: 23843495
Drug: G‐FC (obinutuzumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐FC (obinutuzumab plus fludarabine and cyclophosphamide)
Study: 23843495
Drug: G‐CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CHOP
Study: 23843495
Drug: G‐FC
Normalized name: Gemcitabine and Fluorouracil
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐FC
Study: 18991471
Drug: Saline 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 100 mL
Study: 15845796
Drug: Gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobenate dimeglumine at doses of 0.05, 0.10, or 0.20 mmol/kg
Study: 15845796
Drug: Gadopentetate dimeglumine
Normalized name: Gadopentetate Dimeglumine
DrugBank: Gadopentetic acid (DB00789)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadopentetate dimeglumine at a dose of 0.10 mmol/kg
Study: 1744962
Drug: HA-1A monoclonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: HA-1A monoclonal antibody
Study: 31614361
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of fosfomycin (group A)
Study: 31614361
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of fosfomycin (group B)
Study: 26649536
Drug: 8-week Internet-delivered
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8-week Internet-delivered acceptance-based cognitive behavioral therapy (ACT)
Study: 17971948
Drug: Chinese herbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbs treatment, administered as customized soups, taken twice daily for one week.
Study: 17971948
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment (WM), details not specified.
Study: 3092655
Drug: Enprostil 35
Normalized name: enprostil
DrugBank: Enprostil (DB13824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprostil 35 micrograms administered twenty minutes before each dose of aspirin
Study: 3092655
Drug: Aspirin 600
Normalized name: aspirin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 600 mg given over 48 hours
Study: 18757653
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: Monthly replacement of the ring with no ring-free days
Study: 18757653
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: Monthly replacement of the ring with a 4-day hormone-free interval if breakthrough bleeding/spotting occurred for 5 days or more
Study: 18757653
Drug: 4-day hormone-free
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-day hormone-free interval
Study: 10440160
Drug: Prolonged heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged heparin infusion (12 to 24 h) followed by sheath removal (Group 1)
Study: 10440160
Drug: Early removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early removal of sheaths followed by reinstitution of heparin infusion for 12 to 18 h (Group 2)
Study: 10440160
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further heparin after intervention with early sheath removal (Group 3)
Study: 7759460
Drug: Albuterol powder
Normalized name: albuterol Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol powder 200 micrograms
Study: 7759460
Drug: Albuterol aerosol
Normalized name: Albuterol Inhalation Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol aerosol 180 micrograms
Study: 2334618
Drug: Continuous i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous i.v. infusion of morphine (mean 73.6 mg)
Study: 2334618
Drug: Continuous extradural
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous extradural infusion of 0.25% bupivacaine (mean 192 mg)
Study: 26870683
Drug: GABA-enriched white
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GABA-enriched white rice (11.2 mg GABA/100 g of rice)
Study: 26870683
Drug: Placebo rice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo rice (2.7 mg GABA/100 g of rice)